# Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

> **NCT06361537** · PHASE3 · RECRUITING · sponsor: **Octapharma** · enrollment: 124 (estimated)

## Conditions studied

- Acute Hereditary Angio Edema

## Interventions

- **DRUG:** OCTA-C1-INH
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06361537
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361537, "Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06361537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*